Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib, Rituximab and Methotrexate in Newly Diagnosed PCNSL
NCT05600660Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Aug 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orelabrutinib in primary central nervous system lymphoma (PCNSL), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Started Aug 2022; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT05600660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05600660.